AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Chimeric Therapeutics had announced a share purchase plan last month, with the closing date as 16 June 2023
- The exercise is now complete, and the company has raised AU$1.5 million through the plan
- With the raising done through the Board and management placement, the total funds raised stood at AU$2.5 million
Publicly listed cell therapy company Chimeric Therapeutics (ASX: CHM) -- having therapies including CHM 1101 and CHM 2101 -- has informed about the completion of a share purchase plan (SPP) that the company had announced last month. Notably, Chimeric has raised AU$1.5 million through the SPP. In addition to the SPP, the capital raising done through the Board and management placement brings the total funds to AU$2.5 million.
More
The company informs that in the SPP exercise, new shares were to be offered at either AU$0.04 per share or the price representing a 5% discount to the VWAP of CHM shares during the five trading days up to the closing date (16 June 2023), whichever was lower. Finally, the share price under the SPP was AU$0.035.
Over 43.7 million ordinary shares have been issued to SPP participants by Chimeric on 23 June 2023.
It is pertinent to note that an Extraordinary General Meeting is scheduled by Chimeric for next week (29 June 2023) for considering approval of the Board and management placement.
Chimeric’s ASX shares traded at AU$0.035 (market cap over AU$15.7 million) at the time of writing on 23 June 2023.